SCHEMBL6028149

SCHEMBL6028149

O=C(Cn1cc(Nc2ncnc3cc(OCCCNC4CC4)ccc23)nn1)Nc1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 9/20 0.53
KDR P35968 7/20 0.50
PDGFRB P09619 5/20 0.49
FLT4 P35916 4/20 0.49
PDGFRA P16234 4/20 0.49
FLT1 P17948 2/20 0.49
CDK1 P06493 1/20 0.49
AURKB Q96GD4 7/20 0.48
EGFR P00533 4/20 0.48
FLT3 P36888 3/20 0.48
KIT P10721 3/20 0.48
RIPK2 O43353 2/20 0.48
LCK P06239 2/20 0.48
LYN P07948 2/20 0.48
RET P07949 2/20 0.48
HCK P08631 2/20 0.48
CSNK2A2 P19784 2/20 0.48
MST1R Q04912 2/20 0.48
MAP2K5 Q13163 2/20 0.48
AURKC Q9UQB9 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026358 0.89 PDGFRB (0.53) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6092376 0.88 AURKA (0.53) AURKAKDRPDGFRBPDGFRAAURKB
SCHEMBL6028435 0.87 AURKA (0.56) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6027424 0.87 AURKA (0.51) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6090503 0.86 AURKA (0.56) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6030625 0.86 AURKA (0.56) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6027360 0.86 AURKA (0.55) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6029185 0.86 AURKA (0.59) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6027522 0.85 AURKA (0.57) AURKAKDRPDGFRBFLT4PDGFRA
SCHEMBL6028491 0.85 AURKA (0.55) AURKAKDRPDGFRBFLT4PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US claimed
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US disclosed
EP-1644361-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS Astrazeneca AB (SE) 2006-04-12 EP disclosed
WO-2004113324-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors AURKA, AURKC, AURKB AURKA 1/4885KDR 1914/4885PDGFRB 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.